GL1X · GenesisL1 explorer

Research workbench

Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design

Analyse Differential binding of inhibitors to active and inactive CDK2 provides… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
2C5Y
Type
protein
Length
290 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Cell division protein kinase 2
EC
2.7.1.37
UniProt
P24941
Ligands
MTW
Pockets
1 · best druggability 0.72

Structure

x-ray diffraction · 1 distinct chain · 34% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACell division protein kinase 2 (EC 2.7.1.37)protein29034% helix, 16% strandP24941

Ligands and binding sites

  • MTW · Hydroxy(oxo)(3-{[(2Z)-4-[3-(1H-1,2,4-triazol-1-ylmethyl)phenyl]pyrimidin-2(5H)-ylidene]amino}phenyl)ammonium · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13120.720.8541MTW

Compared structures

  • 2C5Y · Differential binding of inhibitors to active and inactive CDK2 provides insights for drug… · the same entry in another collection · chain A against A, TM-score 1.00
  • P24941 · AlphaFold monomer V2.0 prediction for cyclin-dependent kinase 2 (P24941) · a predicted model of the same protein · chain A against A, TM-score 0.94

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.